Martin J. Joyce

Martin J. Joyce is the current Director at Aldeyra Therapeutics. Prior to this, they were the Chief Financial Officer at Lucid, Inc. from March 2011 to July 2012. An early stage medical device company focused on imaging and telepathology to detect melanoma, basal and squamous skin cancers and inflammatory skin disease. Martin was responsible for organizing the strategy to recapitalize the company through an IPO in December 2011, eliminating convertible debt overhang and related penalties, preventing the bankruptcy of the company. Martin also reworked the company’s strategic plan, outlining value-creating milestones and multiple revenue streams to enhance shareholder value.

From January 2004 to September 2010, Joyce was the Executive Vice President and Chief Financial Officer at BioSphere Medical, Inc., the world market leader in proprietary bioengineered polymer microsphere platform technologies used therapeutically in women’s health and in the delivery of chemotherapeutic compounds. During their time there, they worked directly with the Board of Directors to prepare and execute a plan to sell the company, including leading the due diligence team, and negotiating the definitive merger agreement. Martin also closed a preferred equity round providing needed liquidity to restart the company and prevent delisting from the NASDAQ exchange. In addition, they raised, negotiated and closed a follow on common stock financing. Furthermore, they developed and implemented a comprehensive investor relations campaign which grew BioSphere’s market capitalization 244% in approximately 14 months. This included establishing research analyst, sell-side coverage with five investment banks as well as upgrading the shareholder base to tier-1 life science investors.

Martin also settled litigation related to product distribution and product liability claims against BioSphere that threatened the company’s economic viability, with the resolution of the last lawsuit clearing the way for the sale of the company. In addition, they negotiated clinical research and distribution agreement with Nippon Kayaku Pharmaceuticals in Japan for planned market access of BioSphere’s drug delivery platform for the treatment of liver cancer. Martin also negotiated and closed a joint product collaboration and manufacturing agreement with DuPont. Lastly, they recruited an accounting team to establish financial controls for global implementation of Sarbanes-Oxley.

Martin J. Joyce attended Northeastern University for their BS in Finance and Suffolk University - Sawyer Business School for their M.B.A.